An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT03704077 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Replaced it with another clinical trial

Conditions

Gastric Cancer
Cancer of the Stomach
Stomach Cancer
Gastroesophageal Junction

Interventions

BIOLOGICAL: Relatlimab + Nivolumab
BIOLOGICAL: Nivolumab
DRUG: Paclitaxel
DRUG: Ramucirumab

Sponsor

Bristol-Myers Squibb